Zobrazeno 1 - 10 of 41 pro vyhledávání: '"Chuan-Chuan Wun"'
1
Akademický článek
Safety and efficacy of acalabrutinib plus bendamustine and rituximab in patients with treatment-naive or relapsed / refractory mantle cell lymphoma: phase Ib trial
Autor: Tycel Phillips, Michael Wang, Tadeusz Robak, David Gallinson, Don Stevens, Krish Patel, Safaa Ramadan, Chuan-Chuan Wun, Wojciech Jurczak, Stephen D. Smith
Publikováno v: Haematologica, Vol 999, Iss 1 (2024)
This multicenter, open-label, phase 1b study (ACE-LY-106) assessed the safety and efficacy of acalabrutinib, bendamustine, and rituximab (ABR) in treatment-naive (TN) and relapsed or refractory (R/R) mantle cell lymphoma (MCL). Patients received acal
Externí odkaz: https://doaj.org/article/19f79693265c45379007ce9489c9f51a
Zobrazit plný text záznamu
2
Akademický článek
Phase I/II results of ceralasertib as monotherapy or in combination with acalabrutinib in high-risk relapsed/refractory chronic lymphocytic leukemia
Autor: Wojciech Jurczak, Nagah Elmusharaf, Christopher P. Fox, William Townsend, Amanda G. Paulovich, Jeffrey R. Whiteaker, Fanny Krantz, Chuan-Chuan Wun, Graeme Parr, Shringi Sharma, Veerendra Munugalavadla, Richa Manwani, Emma Dean, Talha Munir
Publikováno v: Therapeutic Advances in Hematology, Vol 14 (2023)
Background: Patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) have limited treatment options. Ceralasertib, a selective ataxia telangiectasia and Rad-3-related protein (ATR) inhibitor, demonstrated synergistic preclinical act
Externí odkaz: https://doaj.org/article/62414b8a3edb44bbb17447d9b2f07ba8
Zobrazit plný text záznamu
4
Safety and Efficacy of Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL)
Autor: Kami J. Maddocks, Wojciech Jurczak, Roser Calvo, Michael Wang, Veerendra Munugalavadla, Tycel Phillips, Tadeusz Robak, David Gallinson, Stephen D. Smith, Chuan-Chuan Wun
Publikováno v: Blood. 138:2416-2416
Background: First-line conventional chemoimmunotherapy in MCL can be improved. Promising results have been seen with Bruton tyrosine kinase inhibitors (BTKis) in combination with venetoclax (V) and an anti-CD20 monoclonal antibody in patients (pts) w
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cdb2d885c661baa6007cdd815f4382b6
https://doi.org/10.1182/blood-2021-146615
Zobrazit plný text záznamu
5
Visit-to-Visit Low-Density Lipoprotein Cholesterol Variability and Risk of Cardiovascular Outcomes
Autor: Andrei Breazna, Franz H. Messerli, Chuan-Chuan Wun, Sripal Bangalore, David A. DeMicco, Investigators
Publikováno v: Journal of the American College of Cardiology. 65:1539-1548
Background Studies demonstrate that lowering low-density lipoprotein cholesterol (LDL-C) using a statin is associated with significant reduction in cardiovascular events. Whether visit-to-visit variability in LDL-C levels affects cardiovascular outco
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c4c86b56472f2787ed583f9722cff924
https://doi.org/10.1016/j.jacc.2015.02.017
Zobrazit plný text záznamu
6
LADA and CARDS: A Prospective Study of Clinical Outcome in Established Adult-Onset Autoimmune Diabetes
Autor: Graham A. Hitman, Richard David Leslie, H. Andrew W. Neil, Thomas O. Ola, Chuan Chuan Wun, David A. DeMicco, Paul N. Durrington, D. John Betteridge, Mohammed I. Hawa, Weihang Bao, Ana Paula Buchan, Helen M. Colhoun, John H. Fuller
Publikováno v: Diabetes Care. 37:1643-1649
OBJECTIVE Diabetes-associated autoantibodies can be detected in adult-onset diabetes, even when initially non–insulin requiring, i.e., with latent autoimmune diabetes. We aimed to identify adult-onset autoimmune diabetes in patients with establishe
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bf3a782882c8b53a6d6c0a157c6a2fd
https://doi.org/10.2337/dc13-2383
Zobrazit plný text záznamu
7
Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels
Autor: John J.P. Kastelein, Terje R. Pedersen, Chuan-Chuan Wun, Anders G. Olsson, Ingar Holme, Rachel Laskey, Ole Faergeman, Matti J. Tikkanen, Rana Fayyad
Publikováno v: International journal of cardiology, 168(4), 3846-3852. Elsevier Ireland Ltd
Tikkanen, M J, Fayyad, R, Faergeman, O, Olsson, A G, Wun, C-C, Laskey, R, Kastelein, J J, Holme, I, Pedersen, T & IDEAL Investigators 2013, ' Effect of intensive lipid lowering with atorvastatin on cardiovascular outcomes in coronary heart disease patients with mild-to-moderate baseline elevations in alanine aminotransferase levels ', International Journal of Cardiology, vol. 168, no. 4, pp. 3846-52 . https://doi.org/10.1016/j.ijcard.2013.06.024
Statins may reduce cardiovascular (CV) morbidity in patients with mild-to-moderate elevations in liver enzyme levels. This post-hoc analysis of the IDEAL study compared intensive versus moderate statin therapy for the prevention of CV events in coron
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f170a1a1f0c87f67ae38de2306951e4
https://doi.org/10.1016/j.ijcard.2013.06.024
Zobrazit plný text záznamu
9
Prediction of Cardiovascular Events in Patients with Ankylosing Spondylitis and Psoriatic Arthritis: Role of Lipoproteins in a High-risk Population
Autor: Terje R. Pedersen, Tore K Kvien, Ingar Holme, David A. DeMicco, Rana Fayyad, Chuan-Chuan Wun, John Betteridge, John C. LaRosa, Anne Grete Semb
Publikováno v: The Journal of Rheumatology. 39:1433-1440
Objective.To evaluate lipids and apolipoproteins as predictors of cardiovascular mortality and morbidity (CVD) in patients with spondyloarthritis (SpA).Methods.In the pooled cohort of participants in the IDEAL, TNT, and CARDS trials, 50 had ankylosin
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c2e10466c451a84361126b4479d69cbc
https://doi.org/10.3899/jrheum.111307
Zobrazit plný text záznamu
10
Relation of Improvement in Estimated Glomerular Filtration Rate With Atorvastatin to Reductions in Hospitalizations for Heart Failure (from the Treating to New Targets [TNT] Study)
Autor: Daniel J. Wilson, Jennifer E. Ho, David A. DeMicco, Allison J. Kean, Prakash Deedwania, David D. Waters, Chuan-Chuan Wun, Andrei Breazna, Kiran K. Khush
Publikováno v: Ho, JE; Waters, DD; Kean, A; Wilson, DJ; Demicco, DA; Breazna, A; et al.(2012). Relation of improvement in estimated glomerular filtration rate with atorvastatin to reductions in hospitalizations for heart failure (from the Treating to New Targets [TNT] study). American Journal of Cardiology, 109(12), 1761-1766. doi: 10.1016/j.amjcard.2012.02.019. UCSF: Retrieved from: http://www.escholarship.org/uc/item/9wj4c5h7
Impaired kidney function often accompanies heart failure (HF) and is associated with a worse prognosis. This post hoc analysis of the Treating to New Targets (TNT) trial examined whether the observed decrease in HF hospitalizations with high- compare
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45c7b9dd72c9fe8bed042f7ba5a4aad0
https://doi.org/10.1016/j.amjcard.2012.02.019
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje